Drug Trial Radar · NCT00635427
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Last checked: Nov 19, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Mar 13, 2008
Primary completion
Dec 28, 2012
Study completion Dec 28, 2012
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety of every other week dosing of Gene-Activated® human glucocerebrosidase (GA-GCB, velaglucerase alfa) intravenously in patients with type 1 Gaucher disease.
Conditions
- Gaucher Disease, Type 1
Interventions
VPRIV®Biological
Intravenous infusion, every other week (EOW)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of Treatment Emergent Adverse EventsTime frame: Baseline to termination of study
Locations
21 sites in 11 countries. Site status is shown where the registry gives one.
Los Angeles Medical Center
Los Angeles, California
Children's Hospital Oakland
Oakland, California
Emory University School of Medicine
Atlanta, Georgia
Children's Memorial Hospital
Chicago, Illinois
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota
Children's Mercy Hospitals & Clinics
Kansas City, Missouri
NYU Medical Center
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
University of Utah Medical Center
Salt Lake City, Utah
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
Your Health S.A.
Buenos Aires, Argentina
All India Institute of Medical Sciences
New Delhi, India
KEM Hospital
Pune, India
Shaare Zedek Medical Center
Jerusalem, Israel
Sociedad Espanola de Socorros Mutuos
Asunción, Paraguay
Instytut "Pomnik-Centrum Zdrowia Dziecka"
Warsaw, Poland
State Institution "Hematology Research Centre RAMS"
Moscow, Russia
Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea
Hospital Universitario Miguel Servet
Zaragoza, Spain
Hospital de La Rabta
Tunis, Jebbari, Tunisia
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.